Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
$0.86
$2.21
$37.35
$6.75M0.02206,730 shs31,300 shs
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
$0.72
$0.72
$0.55
$1.45
$23.72M-0.57580,491 shsN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
$5.70
+2.4%
$7.55
$5.14
$26.60
$17.77M1.6721,790 shs40,090 shs
Pluri Inc. stock logo
PLUR
Pluri
$5.05
-2.9%
$4.85
$3.33
$7.13
$39.74M0.7920,841 shs7,829 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
0.00%0.00%0.00%0.00%0.00%
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
0.00%0.00%0.00%0.00%-40.45%
Passage Bio, Inc. stock logo
PASG
Passage Bio
0.00%+1,286.88%-28.90%-22.78%-69.11%
Pluri Inc. stock logo
PLUR
Pluri
0.00%-6.78%+25.00%+14.06%-10.77%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
2.282 of 5 stars
3.52.00.00.00.61.71.3
Pluri Inc. stock logo
PLUR
Pluri
2.9413 of 5 stars
3.55.00.00.00.63.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
0.00
N/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
2.33
Hold$0.9531.83% Upside
Passage Bio, Inc. stock logo
PASG
Passage Bio
3.00
Buy$150.002,533.89% Upside
Pluri Inc. stock logo
PLUR
Pluri
3.00
Buy$12.00137.62% Upside

Current Analyst Ratings Breakdown

Latest BBI, PLUR, CYTH, and PASG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00
6/2/2025
Pluri Inc. stock logo
PLUR
Pluri
Industrial Alliance Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$12.00
6/2/2025
Pluri Inc. stock logo
PLUR
Pluri
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
$4.64M0.00N/AN/A$9.75 per share0.00
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
$870.73K27.24N/AN/A$0.21 per share3.43
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/A$19.84 per shareN/A
Pluri Inc. stock logo
PLUR
Pluri
$330K120.43N/AN/A$1.00 per share5.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
-$20.06M-$0.90N/AN/AN/A-2,847.19%N/A-307.16%N/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$64.77M-$20.40N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)
Pluri Inc. stock logo
PLUR
Pluri
-$20.89M-$5.53N/AN/A-2,563.29%-4,191.91%-85.40%9/16/2025 (Estimated)

Latest BBI, PLUR, CYTH, and PASG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$0.20N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$4.80-$5.00-$0.20-$0.25N/AN/A
5/13/2025Q3 2025
Pluri Inc. stock logo
PLUR
Pluri
N/A-$0.94N/A-$0.94N/A$0.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/AN/AN/AN/AN/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/AN/A
Pluri Inc. stock logo
PLUR
Pluri
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/A
6.36
6.36
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
N/A
0.17
0.16
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/A
3.74
3.74
Pluri Inc. stock logo
PLUR
Pluri
51.65
4.81
4.81

Institutional Ownership

CompanyInstitutional Ownership
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/A
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
68.55%
Passage Bio, Inc. stock logo
PASG
Passage Bio
53.48%
Pluri Inc. stock logo
PLUR
Pluri
16.59%

Insider Ownership

CompanyInsider Ownership
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
4.53%
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
29.78%
Passage Bio, Inc. stock logo
PASG
Passage Bio
4.30%
Pluri Inc. stock logo
PLUR
Pluri
25.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
162.87 million2.74 millionNot Optionable
Cyclo Therapeutics, Inc. stock logo
CYTH
Cyclo Therapeutics
932.92 million23.12 millionNo Data
Passage Bio, Inc. stock logo
PASG
Passage Bio
1303.12 million2.99 millionOptionable
Pluri Inc. stock logo
PLUR
Pluri
1507.87 million5.83 millionOptionable

Recent News About These Companies

Pluri Inc. reschedules 2025 annual meeting
Pluri: Fiscal Q3 Earnings Snapshot
Pluri Inc. acquires majority stake in Kokomodo Ltd.
Pluri acquires 71% stake in Kokomodo
Pluri’s immune cell expansion technologies gain patents

New MarketBeat Followers Over Time

Media Sentiment Over Time

Brickell Biotech stock logo

Brickell Biotech NASDAQ:BBI

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Cyclo Therapeutics stock logo

Cyclo Therapeutics NASDAQ:CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Passage Bio stock logo

Passage Bio NASDAQ:PASG

$5.70 +0.14 (+2.43%)
As of 11:26 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Pluri stock logo

Pluri NASDAQ:PLUR

$5.05 -0.15 (-2.88%)
As of 11:22 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.